MedTrace Logo

Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.

NCT04175301 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-07-29

No results posted yet for this study

Summary

This is a pilot randomized control trial (RCT) to explore the effects of hydrogen rich water on quality of life in patients with high grade gliomas, receiving focal radiation therapy to the brain concurrent with chemotherapy with Temozolomide.

Conditions

  • Malignant Glioma

Interventions

DRUG

Hydrogen

Each hydrogen tablet contains 80 mg magnesium

DRUG

Placebo oral tablet

Matching placebo tablet also contains 80 mg magnesium

Sponsors & Collaborators

Principal Investigators

  • Agnieszka Kowalska, MD · Stony Brook Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2026-09-05
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175301 on ClinicalTrials.gov